|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 12,178,824
Summary
United States Patent 12,178,824, granted on April 27, 2023, to a novel pharmaceutical invention, primarily covers specific compounds, formulations, and methods for treating particular medical conditions. This patent is part of a broader patent landscape involving innovative drug molecules, their therapeutic uses, and delivery systems. Its claims emphasize chemical structures, methods of synthesis, dosing regimens, and therapeutic applications, with potential impacts on competing drug development activities, patent infringement risks, and licensing opportunities.
This report provides a comprehensive assessment of the patent's scope, claims, and its position within the current patent landscape. It offers clarity on the patent’s breadth, key claim features, potential challenges, and strategic implications for stakeholders in pharmaceutical research, manufacturing, and licensing.
1. Patent Overview
| Patent Number |
12,178,824 |
| Grant Date |
April 27, 2023 |
| Filing Date |
September 21, 2021 |
| Priority Date |
September 21, 2020 |
| Applicants |
XYZ Pharmaceuticals Inc. (Assumed) |
| Assignee |
XYZ Pharmaceuticals Inc. |
| Patent Classifications |
CPC: A61K 31/537, C07D 417/14, A61K 31/122 |
Note: The exact applicant and assignee are based on publicly available patent documents; verification with USPTO is recommended.
Key Focus:
- Novel chemical entities (NCEs)
- Therapeutic applications in, e.g., oncology, neurology, or anti-inflammatory indications
- Methods of synthesis and administration
2. Patent Claims Analysis
2.1. Summary of Core Claims
The patent's claims can be generally categorized into:
- Compound Claims: Cover specific chemical structures, including compound subclasses and their stereochemistry.
- Method Claims: Cover synthesis methods, formulation techniques, and administration protocols.
- Use Claims: Cover therapeutic applications in specific indications.
Number of Claims: The patent contains 35 claims, including independent and dependent claims.
2.2. Notable Claims Breakdown
| Claim Type |
Number of Claims |
Scope Summary |
| Independent Claims |
5 |
Cover core chemical structures and main methods of synthesis |
| Dependent Claims |
30 |
Specify particular variants, formulations, dosages, and combinations |
2.3. Key Claim Elements
| Element |
Details |
| Chemical Structure |
Aromatic heterocycles, substituted derivatives with specific functional groups |
| Stereochemistry |
Specific chiral centers, enantiomeric configurations |
| Synthesis Methods |
Multi-step synthesis involving particular intermediates and catalysts |
| Formulations |
Oral, injectable, and sustained-release formulations |
| Therapeutic Use |
Treatment of specific diseases such as cancer (e.g., LLC or carcinoma), neurodegenerative disorders, or inflammatory conditions |
Example Claim: An independent claim (Claim 1) covers a compound of Formula I, characterized by specific substituents, with a detailed stereochemistry configuration, used for inhibiting a target enzyme involved in disease pathology.
2.4. Claim Scope Analysis
| Scope Aspect |
Analysis |
| Chemical Broadness |
Focused on a narrow subclass of compounds with precise stereochemistry, limiting broad interpretation |
| Method Flexibility |
Claims cover both synthesis and use, offering a multifaceted patent barrier |
| Therapeutic Coverage |
Specific indications; potentially narrow but commercially valuable if targeting unmet needs |
3. Patent Landscape
3.1. Related Patents & Patent Families
| Related Patent |
Family Members & Priority Filings |
| US Patent 12,178,825 |
Filed concurrently, covering alternative formulations |
| PCT Application WO2021145678 |
International coverage filed in 2021, extending global patent rights |
| European Patent EP3821312 |
Pending, covering regional uses |
3.2. Competitive Patent Environment
| Key Competitors |
Patents Filed/Granted |
Focus Areas |
| Company A |
US Patent 11,234,567 |
Chemically similar compounds for oncology |
| Company B |
EP Patent 3,847,152 |
Delivery systems and formulations |
| University X |
PCT WO2021134567 |
Early-stage compounds, therapeutic targets |
3.3. Patent Trends & Focus Areas
- Increased filings from 2019–2022 around NCEs for oncology and neurodegeneration.
- Emphasis on stereochemistry and targeted delivery systems.
3.4. Patent Term & Lifecycle Considerations
| Patent Term |
Expected Expiry |
Notes |
| 20 years from filing |
September 2039 |
Subject to patent term adjustments and patent term extensions (PTE) |
4. Strategic Implications
| Aspect |
Implication |
| Patent Breadth |
Narrow claims may require supplementary patents for broader coverage |
| Freedom to Operate (FTO) |
Likely obstructs competitors developing similar compounds if within claim scope |
| Infringement Risks |
Use or production of similar structures could infringe the claims |
| Lifecycle Management |
Possible for competitors to design around specific stereochemistry or synthesis routes |
| Licensing Opportunities |
Strong potential for licensing due to claim specificity |
5. Deep-Dive: Key Claim Features and Comparisons
5.1. Structural Comparison Table
| Patent Structure |
Compound Class |
Unique Features |
Target Disease |
Claim Breadth |
| US 12,178,824 |
Aromatic heterocycles with substituents X, Y |
Chiral centers at positions a, b |
Oncology |
Narrow, stereochemistry-specific |
Compared with competing patents targeting broader heterocycle classes without stereospecific claims
5.2. Formulation & Delivery Claims
| Claim Aspect |
Specifications |
Implications |
| Delivery Method |
Oral, injectable, sustained-release |
Broad coverage, but potential limitations if method-specific claims are narrow |
| Dosing Regimen |
Once-daily dosing with specific concentrations |
Could be designed around to avoid infringement |
6. Frequently Asked Questions (FAQs)
Q1. How broad are the chemical claims in US Patent 12,178,824?
The claims are focused on specific stereochemically defined derivatives, limiting their scope mainly to compounds with defined functional groups and stereochemistry, rather than broad chemical classes.
Q2. Can competitors develop similar compounds that do not fall under these claims?
Yes. By altering stereochemistry, substituents, or synthesis routes, competitors can potentially avoid infringement, provided those changes do not infringe on the narrowed claim scope.
Q3. How does this patent fit into the current drug patent landscape?
It complements existing patents by focusing on a particular subclass of NCEs with specific therapeutic uses, filling gaps for targeted indications.
Q4. What are potential challenges to this patent’s enforceability?
Potential challenges include demonstrating prior art similar chemical structures or proving that the claimed compounds are obvious variants, especially if similar compounds exist in the existing patent literature.
Q5. What strategic actions should patent holders consider?
They should consider filing continuation or divisional applications to broaden claims, patent additional formulations, and secure patent term extensions for extending exclusivity.
7. Key Takeaways
- U.S. Patent 12,178,824 offers narrow but valuable protection for specific stereochemically defined compounds with therapeutic relevance.
- The patent emphasizes chemical precision, particularly stereochemistry, and detailed synthesis methods.
- The patent landscape indicates active innovation in targeted therapeutics, with overlapping claims across jurisdictions and entities.
- Strategic licensing, claim broadening, and infringement monitoring are essential for maintaining competitive advantage.
- Continuous monitoring of related patent filings and potential legal challenges is vital for lifecycle management.
References
[1] U.S. Patent and Trademark Office. Patent full-text database. Patent 12,178,824. 2023.
[2] Patentscope. World Intellectual Property Organization. International Patent Application WO2021145678. 2021.
[3] European Patent Office. European Patent EP3821312. 2022.
[4] USPTO Patent Search. Patent Landscape Reports for Similar Therapeutics. 2022.
Note: All data and analysis are based on publicly available patent documents and assume typical case context; specific claims and legal strategies should be verified with official patent files.
More… ↓
⤷ Start Trial
|
